June 16, 2025
Swanielle, Inc.

Swanielle, Inc. (Tokyo, Japan) is pleased to announce a new collaborative initiative with Alfresa Holdings Corporation aimed at addressing the growing issue of “Drug Loss” in Japan—the phenomenon in which innovative therapies developed globally fail to reach Japanese patients due to delays or discontinuation in Japan-specific development.
 This initiative is specifically designed for emerging biopharmaceutical companies at intermediate development stages who are considering entering the Japanese market but face common barriers such as limited internal resources, regulatory complexity, or budget constraints.
 By combining Alfresa’s extensive healthcare infrastructure with Swanielle’s deep expertise in Japan-focused development, the initiative offers a streamlined, resource-supported pathway for global innovators to evaluate or pursue clinical and commercial presence in Japan.
 Through this collaboration, Alfresa and Swanielle aim not only to support overseas biopharma companies but also to reduce Drug Loss and help deliver needed treatments to Japanese patients in a timely manner.

For inquiries:
Hiroshi Yamabe, CEO, Swanielle, Inc.
contact form